Asia-Pacific to Convene Regenerative Medicine Leaders at CGT World Asia 2026

#CGTAsia2026: Driving Innovation in Regenerative Medicine

The Asia-Pacific region is set to host a significant event in regenerative medicine in 2026: the 9th Cell & Gene Therapy World Asia Congress (#CGTAsia2026). Organized by IMAPAC, this conference is positioned as the premier knowledge-sharing platform for cell and gene therapy (CGT) in the region. Its mission is to drive breakthroughs in research, clinical applications, and manufacturing, while also addressing the unique challenges faced by Asia in CGT development. As the Asia-Pacific region increasingly emerges as a global leader in regenerative medicine, #CGTAsia2026 aims to invigorate industry growth and accelerate the translation of cutting-edge technologies into clinical practice.

Conference Highlights and Scope

The congress is designed to bring together stakeholders from across the cell and gene therapy ecosystem, providing a platform for in-depth discussions on the latest advancements in cell therapies, gene therapies, and CAR-T technologies. #CGTAsia2026 will be held concurrently with the RNA World Asia 2026 and the Oligonucleotides & Peptides World Asia Congress 2026, offering attendees multidisciplinary exchange and collaboration opportunities. The event is expected to draw over 50 industry experts and more than 500 senior decision-makers from the Asia-Pacific region. Participants will share insights spanning the entire spectrum of CGT, from scientific discovery and first-in-human clinical trials to next-generation cell therapy advancements, therapeutic platform development, scaled manufacturing, and delivery. The congress will also feature the "2026 Asia-Pacific Cell & Gene Therapy Excellence Awards" ceremony, recognizing outstanding contributions by organizations and individuals in the field.

Spotlight on Expert Contributions

The congress will feature a lineup of experts who will share insights into the dynamic field's latest trends, challenges, and developments. Among them is Mr. Chethan A J, Assistant Director of Quality Assurance and Regulatory Affairs at the Center for Ocular Regeneration (CORE), LV Prasad Eye Institute, India. Mr. Chethan specializes in Quality Management Systems, Risk Management, and Indian Regulatory Affairs. With over 13 years of experience in cell and gene therapy, he has led teams in various aspects of Chemistry, Manufacturing, and Controls (CMC), including manufacturing, quality assurance, and regulatory affairs. Under his leadership, CORE's GMP manufacturing facility successfully obtained CT-11 manufacturing and test licenses for five unique cell therapy products and CT-06 clinical trial licenses for two unique cell therapy products (Phase I) from the Indian FDA (CDSCO). Mr. Chethan is proficient in establishing Quality Management Systems for cell therapy products that comply with cGMP standards. He holds a master's degree in Medical Biochemistry from Manipal University, an MBA in Total Quality Management, a Diploma in GMP, a Six Sigma Green Belt certification, and is a certified Internal Auditor for ISO 9001:2015 QMS. He is also an active member of the Society of Quality Assurance (SQA) and the Indian Society for Clinical Research (ISCR).

Asia's Growing Role in CGT: Other Key 2026 Events

Beyond #CGTAsia2026, the year 2026 will see a series of other pivotal conferences focusing on cell and gene therapy biotechnology in Asia, underscoring the region's strategic importance in global regenerative medicine. These include:

• The 4th Cell & Gene Therapy Innovation & Access Congress 2026: Organized by Biopharma Asia, this congress will cover the entire CGT research and development pipeline, from early-stage research to manufacturing and scaled application. It will feature two main tracks: "Therapeutic Discovery & Engineering" and "Manufacturing Enablement & Translation."
• ISCT Asia 2026 Regional Meeting: Hosted by the International Society for Cell & Gene Therapy (ISCT), this meeting will take place from September 2-5, 2026, in Singapore.
• The 10th Asia Cell and Gene Therapy Innovation Summit 2026: Organized by TanSi Biotech, this summit will be held concurrently with the ISCT Asia 2026 Regional Meeting.

The concentrated schedule of these high-level conferences is expected to further solidify Asia's position as an innovation hub in the global CGT landscape, fostering deep collaboration and knowledge exchange both within and beyond the region.

Aoweisi Health's Commitment

As professional editors for Aoweisi Health Management's stem cell research information platform, we recognize the profound significance of these advanced conferences in promoting the development of stem cell and regenerative medicine. #CGTAsia2026 and its co-located events will provide a crucial platform for global researchers, clinicians, industry leaders, and policymakers to converge, share insights, and inspire innovation. By delving into the latest scientific discoveries, technological breakthroughs, and regulatory challenges, these conferences will accelerate the translation of cell and gene therapies from laboratories to clinical practice, ultimately benefiting a wide range of patients. Aoweisi Health Management is committed to continuously monitoring and reporting on such premier industry events, dedicated to delivering cutting-edge research information to our readers, and collectively advancing the field of stem cell and regenerative medicine for the betterment of human health and well-being.